Immunotherapy has revolutionized the contemporary oncology landscape, with durable
responses possible across a range of cancer types. However, the majority of cancer patients …

While cancer immunotherapy can produce dramatic responses, only a minority of patients
respond to treatment. Reliable response biomarkers are needed to identify responders, and …

Immune checkpoint inhibitors have made rapid advances, resulting in multiple Food and
Drug Administration–approved therapeutics that have markedly improved survival. However …

Purpose: The lack of a timely and reliable measure of response to cancer immunotherapy
has confounded understanding of mechanisms of resistance and subsequent therapeutic …

Nivolumab has recently received approval by the Food and Drug Administration for
treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with …

Introduction. Hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic
shunt (TIPS) placement remains a leading adverse event. Controversy remains regarding …

Y90 radioembolization is an alternative to transarterial chemoembolization for the intra-
arterial treatment of hepatocellular carcinoma (HCC). However, the optimal treatment of …

Background Cancer immunotherapy research is expanding to include a more robust
understanding of the mechanisms of treatment response and resistance. Identification of …

Purpose: Cancer immunotherapy has markedly improved the prognosis of patients with a
broad variety of malignancies. However, benefits are weighed against unique toxicities, with …

PURPOSE: To examine the effect of percutaneous thermal ablation of renal masses on renal
function among patients with baseline chronic kidney disease (CKD). MATERIALS AND …